MindBio Therapeutics (MBIO) | WebDisclosure

Basculer en Français

8299	Companies
114948	Keywords
55352	Articles
62471	Press releases

Home
Companies
MindBio Therapeutics

BRIEF

published on 05/02/2024 at 10:05, 6 months 19 days ago

MindBio Therapeutics Advances Women’s Health and Depression Treatment Trials

Clinical Trials Microdosing LSD MindBio Therapeutics Women's Health Depression Treatment
BRIEF

published on 05/02/2024 at 10:05, 6 months 19 days ago

MindBio Therapeutics fait progresser les essais sur la santé des femmes et le traitement de la dépression

Essais Cliniques MindBio Thérapeutique Microdosage Du LSD Santé Des Femmes Traitement De La Dépression
PRESS RELEASE

published on 05/02/2024 at 10:00, 6 months 19 days ago

MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. presents groundbreaking women's health trials for microdosing treatments, showcasing Dr. Rachael Sumner and upcoming data release on Phase 2A trial results. Chief Executive Justin Hanka discusses future growth plans

Clinical Trials Mental Health MindBio Therapeutics Corp. Women's Health Trials Microdosing Treatments
PRESS RELEASE

published on 05/02/2024 at 10:00, 6 months 19 days ago

MindBio Therapeutics Scientists Present Landmark Women’s Health Trials. Company To Release Phase 2A Depression Trial Secondary Data This Month
MindBio Therapeutics Corp. showcases women's health trials and upcoming data presentation on Phase 2A trial of MB22001 for Major Depressive Disorder. Company pioneering microdosing LSD for mental health conditions

MindBio Therapeutics Corp. MB22001 Microdosing LSD Women's Health Trials Phase 2A Trial
BRIEF

published on 05/01/2024 at 11:25, 6 months 20 days ago

MindBio Therapeutics explore la double inscription au milieu d'essais cliniques réussis

Depression Phase 2b Essais Cliniques MindBio Thérapeutique Microdosage Du LSD
BRIEF

published on 05/01/2024 at 11:25, 6 months 20 days ago

MindBio Therapeutics Explores Dual Listing Amid Successful Clinical Trials

Clinical Trials Microdosing LSD Phase 2b MindBio Therapeutics Depressive Disorder
PRESS RELEASE

published on 05/01/2024 at 11:20, 6 months 20 days ago

MindBio Is Exploring Dual Listing on A Senior Exchange with Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
MindBio announces successful completion of Phase 1 and Phase 2a Clinical Trials for MB22001 in treating Major Depressive Disorder. Company plans dual listing on senior exchange

Dual Listing Clinical Trials MB22001 MindBio Therapeutics Depressive Disorder
BRIEF

published on 04/30/2024 at 12:10, 6 months 21 days ago

MindBio Therapeutics lance des essais cliniques révolutionnaires pour la santé des femmes

MB22001 Essais Cliniques Microdosage Du LSD Santé Des Femmes PMS Et PMDD
BRIEF

published on 04/30/2024 at 12:10, 6 months 21 days ago

MindBio Therapeutics Launches Groundbreaking Clinical Trials for Women's Health

Clinical Trials MB22001 Microdosing LSD Women's Health PMS And PMDD
PRESS RELEASE

published on 04/30/2024 at 12:05, 6 months 21 days ago

MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
MindBio Therapeutics Corp. has received regulatory approval for clinical trials using MB22001 to address PMS and PMDD in menstruating individuals. The trials aim to assess the drug's mood-related effects during different menstrual phases

Clinical Trials MindBio Therapeutics Corp. MB22001 PMS PMDD

Accesswire

Published on 11/21/2024 at 14:30, 32 minutes ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Published on 11/21/2024 at 14:30, 32 minutes ago

Sarama Announces Equity Placement of Up to A$2M and Issue of Equity for Debt
Published on 11/21/2024 at 14:15, 47 minutes ago

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 1 hour 2 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 1 hour 2 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:16, 46 minutes ago

EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 47 minutes ago

ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 1 hour 2 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:41, 1 hour 21 minutes ago

Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Published on 11/21/2024 at 13:15, 1 hour 47 minutes ago

NOTICE OF ANNUAL GENERAL MEETING

Les Echos

Published on 11/21/2024 at 06:58, 8 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 8 hours 4 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 8 hours 4 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 18 hours 54 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 19 hours 42 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE